Abstract：
Respiratory tract infections caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses are persistent and critical. The Cobas Liat SARS-CoV-2 & influenza A/B assay (Multiplex Liat), the FDA-authorized point-of-care reverse transcriptase polymerase chain reaction (RT-PCR) assay, has a turnaround time of 20 min and high accuracy. This study evaluates the pooled performance of this assay to provide practical information. This meta-analysis was registered in PROSPERO (registration number: CRD42023467579). A systematic literature search was conducted within PubMed, Ovid-EMBASE, and the Cochrane Library for articles evaluating the accuracy of the Multiplex Liat assay through September 2023. A random-effects model was used to calculate the pooled diagnostic values with real-time RT-PCR (rRT-PCR) as a reference test. A total of 4,705 samples from eight studies were included in the primary meta-analysis. The overall pooled sensitivity and specificity of Multiplex Liat were 100.0 % (95 % confidence interval [CI] = 96.7 %-100.0 %) and 99.7 % (95 % CI = 98.7 %-99.9 %), respectively. The presence of variants of concern or in-house rRT-PCR assays as reference standards did not significantly affect the pooled diagnostic performance of the Multiplex Liat. When 5,333 samples from nine studies were assessed for sensitivity, the pooled sensitivity was 100.0 % (95 % CI = 85.8 %-100.0 %) without a significant difference. This meta-analysis demonstrates the usefulness of Multiplex Liat for the detection of SARS-CoV-2 based on pooled diagnostic values. These practical findings may facilitate appropriate settings for the diagnosis and management of patients with respiratory tract infections.
摘要：
由严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）和流感病毒引起的呼吸道感染是持续和关键的。CobasLiatSARS-CoV-2和A/B流感测定（多重Liat），FDA授权的即时逆转录酶聚合酶链反应（RT-PCR）测定，具有20分钟的周转时间和高精度。本研究评估了该测定的汇集性能以提供实用信息。该荟萃分析在PROSPERO（注册号：CRD42023467579）中注册。在PubMed进行了系统的文献检索，Ovid-EMBASE,和Cochrane图书馆的文章评估到2023年9月的多重Liat测定的准确性。使用随机效应模型以实时RT-PCR（rRT-PCR）作为参考测试来计算合并的诊断值。来自8项研究的4,705份样本被纳入主要荟萃分析。多重Liat的总体合并敏感性和特异性分别为100.0%（95%置信区间[CI]=96.7%-100.0%）和99.7%（95%CI=98.7%-99.9%），分别。作为参考标准的关注变体或内部rRT-PCR测定的存在没有显著影响多重Liat的合并诊断性能。当来自9项研究的5333个样本被评估敏感性时，合并敏感性为100.0%(95%CI=85.8%-100.0%),无显著差异.这项荟萃分析证明了MultiplexLiat用于基于合并诊断值检测SARS-CoV-2的有用性。这些实际发现可能有助于为呼吸道感染患者的诊断和管理提供适当的设置。
